CaroSpir (spironolactone oral suspension) 25mg/5mL is now available in a unit dose cup.

The Food and Drug Administration (FDA) approved CaroSpir in August 2017 for adults who have difficulty swallowing or who cannot swallow tablets. Prior to the approval, patients had to obtain liquid spironolactone as a pharmacy compounded formulation, which commonly had limited shelf life. 

In addition to the 118mL and 473mL bottles, CaroSpir is now supplied in single-dose 5mL cups in cartons containing 10 cups. The new packaging allows for ease of administration and convenience for health care providers by eliminating the time needed for compounding or pouring at the bedside.

CaroSpir is indicated for the treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure.

It is also approved for use as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents, as part of comprehensive cardiovascular risk management; and to manage edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction.

“CaroSpir is a convenient, safe, and approved liquid option for patients who need it, and the new unit dose cup makes administering CaroSpir even easier for busy health care workers,” said Gerald Sakowski, CEO of CMP Pharma, Inc.


CMP Pharma, Inc. announces unit dose packaging for CaroSpir®, the first and only FDA-Approved spironolactone oral suspension. News release. CMP Pharma, Inc. Accessed October 18, 2021.